29
Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology University California Irvine Orange, California

Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology

Embed Size (px)

Citation preview

Page 1: Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology

Hemodynamics: essentials for future TAVR and mitral valve disease

Morton J. Kern, MDProfessor of Medicine

Chief of CardiologyAssociate Chief CardiologyUniversity California Irvine

Orange, California

Page 2: Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology

Etiology of Aortic Stenosis From the Euro Heart Survey

Goldbarg, S. H. et al. J Am Coll Cardiol 2007;50:1205-1213

Page 3: Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology

J Am Coll Cardiol. 2012;60(3):169-180.

Pathophysiology of AS

Page 4: Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology

Tri/MV valves open

Pa/Ao valves are closed

Pa/Ao valves open

Tri/MV valves close

Pa/Ao valves close

Tri/MV valves opensystole

=Valve action

Page 5: Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology

Mechanism of AS: LV-Ao Gradient

Consequences of LV-Ao Gradient:

1. late peaking Systolic murmur

2. Single A23. Slow pulse upstroke

Page 6: Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology

BAMC Case #3117: Patient: 61 yo maleDx: 3V CAD filter: 50 Hz/ sample 250 Hz

Pre ContrastNormal LV and Aortic Pressure Fluid-filled system micromanometer transducers Fluid filled, FA sheath

Page 7: Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology

P-P gradMean Grad

Peak instantaneous vs P-P

Unshifted=larger Grad

LV

Fusberg and Feldman T, Cath and CV Int 53:553;2001

Hemodynamic Technique

Page 8: Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology

Techniques for Aortic Valve Gradient Measurement

• Single Catheter LV-Ao pullback• LV and Femoral Sheath• LV and Long aortic sheath• Bilateral femoral access• Double-lumen pigtail catheter• Transeptal LV access with ascending Ao• Pressure Guidewire with ascending Ao• Multi-transducer micromanometer catheters

Fusberg and Feldman T, Cath and CV Int 53:553;2001

Page 9: Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology

Calculating Aortic Valve Area• AVA: Gorlin equation

• AVA: Hakke formula (“poor man’s Gorlin”)– Assumes HR*SEP*44.3 = 1000 in most patients– Valid for HR ~65-100

AVA = cardiac output (L/min)/√Peak-Peak Pressures

Page 10: Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology

Grading Severity of Aortic Stenosis

AVA AVA IndexAortic Stenosis (cm2) (cm2/m2)

Mild >1.5 >0.9

Moderate 1.1-1.5 >0.6-0.9

Severe <0.8-1.0 <0.4-0.6

Page 11: Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology
Page 12: Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology
Page 13: Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology

Hemodynamic Differentiation of LVOT Obstruction

AS HOCM

3 Differentiating featuresa. Aortic upstrokeb. Pulse pressurec. Contour –spike/dome

Page 14: Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology

Low Gradient, Low EF AS?

LVEF 25%P-P gradient 30mmHgCO = 3.2l/m FickAVA = 0.7cm2

Page 15: Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology

Base 10 Dob+Pace 80 20 Dob + Pace 95

Dobutamine challenge for LG AS

P-P = 50mmHgCO = 4.2l/m

AVA = 0.6cm2

Page 16: Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology

Grayburn, P. A. Circulation 2006;113:604-606

What should you do with Symptomatic AS patient, low gradient, low flow? The Dobutamine Challenge

AVA = 0.7cm2

AVA = 1.0cm2

AVA = 1.5cm2

Fixed area

Page 17: Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology

Chiam, P. T.L. et al. J Am Coll Cardiol Intv 2008;1:341-350

Edwards-Sapien PHVCoreValve PHV

Page 18: Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology
Page 19: Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology
Page 20: Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology

Pre- Post 26mm Sapien Edwards

Anachrotic shoulder, dichrotic notch

Diastolic dysfunction?Delayed upslope

Page 21: Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology

AS+AI

Page 22: Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology
Page 23: Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology

Normal LA and LV diastolic pressures LA-LV Diastolic Gradient

Page 24: Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology

PCW does not always equal LA

Page 25: Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology

Hemodynamics and Doppler Echo findings before MVBP

Page 26: Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology
Page 27: Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology

Hemodynamic and Doppler Echo findings after MVBP

Page 28: Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology
Page 29: Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology

Hemodynamics for Structrual Heart Disease

Low Gradient ASComplications of AVP – AIAS vs. HOCMMitral Regurgitation after MVP for MSDiastolic CHF – constrictive v RestrictiveTamponade

For your own review consider Intracardiac Shunts